By May/June 2025 the MHRA had cleared its backlog, so there was no queue of old cases. DCVax-L was the only brain cancer therapy with a confirmed UK marketing authorisation application actively under review, verified by NICE’s April 2, 2025 tracker update and a Parliamentary written answer on April 28, 2025. Under FOIA Section 22(1), CHM minutes are routinely withheld when they concern a pending authorisation. Taken together, that makes DCVax-L the only plausible “brain cancer medicine” on the CHM’s agenda in that period.
Bullish
Market Data 
Markets 
AI
